Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML

NCT00123487 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

638

Enrollment

INDUSTRY

Sponsor class

Conditions

Myeloid Leukemia, Chronic, Accelerated Phase
Leukemia, Lymphoblastic, Acute, Philadelphia-Positive

Interventions

DRUG: dasatinib
DRUG: dasatinib

Sponsor

Bristol-Myers Squibb